Assyro AI

Orange Book product · Brand (NDA)

DEFINITY

PERFLUTREN

Brand (NDA)NDA 021064RX LANTHEUS MEDCL

At a glance

Jul 31, 2001

Approved

Brand (NDA)

Application

Not listed

TE code

9

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    Jul 31, 2001

    25 yr 3 mo ago

  2. Today

  3. Patent 10583207 expires

    Listed method-of-use patent (U-665) expiration.

    Dec 28, 2035

    in 9 yr 8 mo

  4. Patent 10583208 expires

    Listed method-of-use patent (U-665) expiration.

    Mar 16, 2037

    in 10 yr 11 mo

  5. Patent 11266750 expires

    Listed method-of-use patent (U-665) expiration.

    Mar 16, 2037

    in 10 yr 11 mo

  6. Patent 11529431 expires

    Listed method-of-use patent (U-665) expiration.

    Mar 16, 2037

    in 10 yr 11 mo

  7. Patent 11857646 expires

    Listed method-of-use patent (U-665) expiration.

    Mar 16, 2037

    in 10 yr 11 mo

  8. Patent 11925695 expires

    Listed method-of-use patent (U-665) expiration.

    Mar 16, 2037

    in 10 yr 11 mo

  9. Patent 12161730 expires

    Listed method-of-use patent (U-665) expiration.

    Mar 16, 2037

    in 10 yr 11 mo

  10. Patent 9789210 expires

    Listed method-of-use patent (U-665) expiration.

    Mar 16, 2037

    in 10 yr 11 mo

  11. Patent 10588988 expires

    Listed method-of-use patent (U-665) expiration.

    May 04, 2037

    in 11 yr

Pharmaceutical detail

Active ingredient

PERFLUTREN

Strength

13.04MG/2ML (6.52MG/ML)

Dosage form

INJECTABLE

Route

INTRAVENOUS

TE code

Not listed

Application

NDA 021064

Product number

001

Marketing status

RX

Reference listed drug (RLD)

Yes

Reference standard (RS)

Yes

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Listed patents (9)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
10583207Dec 28, 2035in 9 yr 8 mo
U-665
10583208Mar 16, 2037in 10 yr 11 mo
U-665
11266750Mar 16, 2037in 10 yr 11 mo
U-665
11529431Mar 16, 2037in 10 yr 11 mo
U-665
11857646Mar 16, 2037in 10 yr 11 mo
U-665
11925695Mar 16, 2037in 10 yr 11 mo
U-665
12161730Mar 16, 2037in 10 yr 11 mo
U-665
9789210Mar 16, 2037in 10 yr 11 mo
U-665
10588988May 04, 2037in 11 yr
U-665
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.